Allison Bratzel
Stock Analyst at Piper Sandler
(4.91)
# 241
Out of 4,969 analysts
264
Total ratings
59.5%
Success rate
38.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Reiterated: Buy | $58 → $60 | $51.85 | +15.72% | 14 | Sep 15, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $56 | $25.07 | +123.37% | 6 | Sep 8, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $88 → $90 | $66.41 | +35.52% | 9 | Sep 1, 2026 | |
| AKBA Akebia Therapeutics | Reiterated: Buy | $4 | $0.9629 | +315.41% | 18 | Aug 17, 2026 | |
| ALXO ALX Oncology Holdings | Reiterated: Buy | $4 | $1.93 | +107.79% | 7 | Aug 17, 2026 | |
| ARDX Ardelyx | Reiterated: Buy | $16 → $15 | $3.52 | +326.14% | 9 | Aug 17, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,075 → $1,215 | $990.54 | +22.66% | 34 | Aug 17, 2026 | |
| BHVN Biohaven | Reiterated: Buy | $30 | $12.64 | +137.34% | 7 | Aug 17, 2026 | |
| CDXS Codexis | Reiterated: Buy | $9 → $8 | $1.48 | +440.54% | 12 | Aug 17, 2026 | |
| COGT Cogent Biosciences | Reiterated: Buy | $52 → $55 | $33.41 | +64.62% | 9 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $0.561 | +78.25% | 10 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $4.33 | +177.14% | 6 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $110 → $130 | $122.19 | +6.39% | 13 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 → $94 | $51.44 | +82.74% | 14 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $12.88 | +132.92% | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $68 | $13.61 | +399.63% | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $40 → $49 | $45.35 | +8.05% | 10 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 → $68 | $65.79 | +3.36% | 21 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $11.17 | +7.43% | 7 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $13.11 | +6.79% | 10 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $165 → $175 | $113.58 | +54.08% | 13 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $26 → $4 | $1.88 | +112.77% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3 → $0.5 | $0.0001 | +499,900.00% | 5 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $41.02 | n/a | 6 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 → $20 | $8.74 | n/a | 6 | Mar 14, 2024 |
Scholar Rock Holding
Sep 15, 2026
Reiterated: Buy
Price Target: $58 → $60
Current: $51.85
Upside: +15.72%
Tyra Biosciences
Sep 8, 2026
Reiterated: Buy
Price Target: $56
Current: $25.07
Upside: +123.37%
BioMarin Pharmaceutical
Sep 1, 2026
Reiterated: Buy
Price Target: $88 → $90
Current: $66.41
Upside: +35.52%
Akebia Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $4
Current: $0.9629
Upside: +315.41%
ALX Oncology Holdings
Aug 17, 2026
Reiterated: Buy
Price Target: $4
Current: $1.93
Upside: +107.79%
Ardelyx
Aug 17, 2026
Reiterated: Buy
Price Target: $16 → $15
Current: $3.52
Upside: +326.14%
argenx SE
Aug 17, 2026
Reiterated: Buy
Price Target: $1,075 → $1,215
Current: $990.54
Upside: +22.66%
Biohaven
Aug 17, 2026
Reiterated: Buy
Price Target: $30
Current: $12.64
Upside: +137.34%
Codexis
Aug 17, 2026
Reiterated: Buy
Price Target: $9 → $8
Current: $1.48
Upside: +440.54%
Cogent Biosciences
Aug 17, 2026
Reiterated: Buy
Price Target: $52 → $55
Current: $33.41
Upside: +64.62%
Aug 17, 2026
Reiterated: Hold
Price Target: $1
Current: $0.561
Upside: +78.25%
Aug 17, 2026
Reiterated: Buy
Price Target: $12
Current: $4.33
Upside: +177.14%
Aug 17, 2026
Reiterated: Buy
Price Target: $110 → $130
Current: $122.19
Upside: +6.39%
Aug 17, 2026
Reiterated: Buy
Price Target: $100 → $94
Current: $51.44
Upside: +82.74%
Aug 17, 2026
Reiterated: Buy
Price Target: $30
Current: $12.88
Upside: +132.92%
Aug 17, 2026
Reiterated: Buy
Price Target: $68
Current: $13.61
Upside: +399.63%
Aug 17, 2026
Reiterated: Hold
Price Target: $40 → $49
Current: $45.35
Upside: +8.05%
Aug 17, 2026
Reiterated: Buy
Price Target: $49 → $68
Current: $65.79
Upside: +3.36%
Aug 7, 2026
Reiterated: Buy
Price Target: $12
Current: $11.17
Upside: +7.43%
Aug 7, 2026
Reiterated: Buy
Price Target: $14
Current: $13.11
Upside: +6.79%
Jul 9, 2026
Rated: Buy
Price Target: $165 → $175
Current: $113.58
Upside: +54.08%
May 8, 2026
Downgraded: Hold
Price Target: $26 → $4
Current: $1.88
Upside: +112.77%
Jan 23, 2026
Downgraded: Hold
Price Target: $3 → $0.5
Current: $0.0001
Upside: +499,900.00%
Jul 18, 2024
Reiterated: Buy
Price Target: $22
Current: $41.02
Upside: n/a
Mar 14, 2024
Upgraded: Buy
Price Target: $8 → $20
Current: $8.74
Upside: n/a